Cookie Policy         The Babraham Research Campus is also home to The Babraham Institute

  Babraham Bioscience Technologies
        Babraham Research Campus - Cambridge - UK


Video Library


Press Releases and Media Reports 2016


Mission Therapeutics

Mission Therapeutics Appoints Colin Goddard as Chairman. More...

5th December 2016


Bicycle Therapeutics

Bicycle Therapeutics Announces Broad Partnership with AstraZeneca to Develop Bicyclic Peptides (Bicycles™) More...

1st December 2016


Babraham Research Campus

Over £500M Investment made in life-science companies located at the Babraham Research Campus, Cambridge over last two years. More...

30th November 2016


Babraham Bioscience Technologies

A new conference and social facilities building, to be named The Cambridge Building, has been completed by SDC Builders and handed over to Babraham Bioscience Technologies. More...

22nd November 2016


Crescendo Biologics

Crescendo Biologics and Takeda Enter Collaboration for Humabody®-based Therapeutics Worth up to $790m. More...

10th October 2016


Artios Pharma

A new private company has been launched in Cambridge on the wings of a $33.2 million fundraising to develop novel cancer treatments targeting the DNA Damage Response (DDR). More...

21st September 2016



F-star Announces Collaborative Agreement with Denali Therapeutics for the Development of a Multispecific Antibody Platform to Deliver Therapeutics Across the Blood-Brain Barrier. More...

25th August 2016


Axol and Metrion

Axol, the human cell culture specialists, join experts in ion channel research to study human iPSC-derived cardiomyocytes for drug discovery applications. More...

26th July 2016


Innova Biosciences

Innova Biosciences, a specialist provider of bioconjugation products and services, today announced the launch of a carboxylated derivative of its unique InnovaCoat® GOLD 40 nm nanoparticles. The new product enables customers to quickly generate highly stable covalent gold-antibody conjugates at R&D and manufacturing scales. More...

25th July 2016


Bicycle Therapeutics

Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptides (BicyclesTM) platform, announced today the appointment of Stephen J. Hoffman, M.D., Ph.D., as Chairman of the Board of Directors. More...

18th July 2016



Cambridge-based biopharma powerhouse Abzena has formed a UK-US joint antibodies venture with Dallas business Baylor Scott & White Research to develop novel immunotherapies. More...

14th July 2016



F-star announces funding and collaboration extension with new Christian Doppler Lab for Innovative Immunotherapeutics. More...

14th July 2016



F-star, a biopharmaceutical company developing novel bispecific antibodies with a focus on immuno-oncology, today announced that it has entered into an agreement with CMC Biologics for GMP manufacturing of its lead mAb2 programme, FS118, ahead of future clinical studies. More...

7th June 2016



DefiniGEN, a leading provider of stem cell life science products, has announced that it has raised £1.5m ($2.29m) in follow-on funding. The investment will be used to fund the commercial launch of new pancreatic and lung stem cell products for drug discovery and regenerative medicine. More...

23rd May 2016


Bicycle Therapeutics

Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptides (BicyclesTM) platform, announced today it has established U.S. operations with headquarters in Cambridge, Massachusetts and named Rosamond Deegan, MBA, as President and Chief Business Officer. More...

26th April 2016


Innova Biosciences Limited
Cambridge life science business Innova Biosciences, which provides bioconjugation products and services, has expanded its UK footprint to enable the company to increase its laboratory space. More...
26th April 2016



F-star moves into new facility in Cambridge, UK and expands team further with appointment of

Michael Davies as VP Protein Sciences


F star, a biopharmaceutical company developing novel immunooncology bispecific antibodies, today announced the opening of its new facility in the Eddeva building on the Babraham Research Campus in Cambridge, UK. The Company also announced the appointment of Michael Davies as VP Protein Sciences. More...

18 March 2016



F-star Enters into Collaborative Discovery & Development Agreement with AbbVie for Bispecific Antibodies in Immuno-oncology


F star, today announced that it has entered into a collaboration and license agreement with AbbVie to research and develop bispecific antibodies in immuno-oncology. Financial terms were not disclosed. More...

11 January 2016



Cambridge-based Kymab which specialises in human monoclonal antibody technology, is working with a leading US university on a new cancer drug discovery and development programme.


Kymab has entered an alliance with The University of Texas MD Anderson's Oncology Research for Biologics and Immunotherapy Translation (ORBIT) unit. More...

7 January 2016




Babraham Bioscience Technologies Ltd - Cambridge - United Kingdom